As Nash shifts again, the focus remains on Genfit’s big readout
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Keeping corporations healthy is good business for Livongo
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
Novo goes small with big Dicerna deal
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
Upcoming events – Adamas and Ascendis look for new paths forward
Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
Pricing questions remain as Novo gets the nod for oral sema
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Should the diabetes development road end for Sanofi?
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
Go or no go? Novo awaits call on oral sema
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.